Valneva SE Company Description

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.

It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.

The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus.

It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally.

The company was founded in 1998 and is based in Saint-Herblain, France.

Valneva SE

Country	France
Founded	1998
Industry	Biological Products, Except Diagnostic Substances
Employees	713
CEO	Thomas Lingelbach

Contact Details

Address: 6 rue Alain Bombard Saint-Herblain, 44800 France
Phone	33 2 28 07 37 10
Website	valneva.com

Stock Details

Ticker Symbol	AYJ
Exchange	Frankfurt Stock Exchange
Fiscal Year	January - December
Reporting Currency	EUR
SIC Code	2836

Key Executives

Name	Position
Thomas Lingelbach	Chief Executive Officer
Peter Buhler	Chief Financial Officer
Vincent Dequenne	Chief Operating Officer
Joshua Drumm	Head of Investor Relations